Heron therapeutics announces the inclusion of zynrelef® as a qualifying product under the proposed 2025 non-opioid policy for pain relief under the opps and the asc payment system

San diego , july 15, 2024 /prnewswire/ -- heron therapeutics, inc. (nasdaq: hrtx) ("heron" or the "company"), a commercial-stage biotechnology company, today announced that zynrelef® (bupivacaine and meloxicam) is included in the proposed 2025 non-opioid policy for pain relief under the medicare hospital outpatient prospective payment system ("opps") and the medicare ambulatory surgical center ("asc") payment system (the "proposed rule") as a qualifying product effective april 1, 2025. this proposed rule for payment within hospital outpatient departments ("hopds") and ascs was issued by the centers for medicare & medicaid services ("cms").
ASC Ratings Summary
ASC Quant Ranking